TY - JOUR
T1 - CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells
AU - Herszfeld, Daniella
AU - Wolvetang, Ernst
AU - Langton-Bunker, Emma
AU - Chung, Tung-Liang
AU - Filipczyk, Adam A
AU - Houssami, Souheir
AU - Jamshidi, Pegah
AU - Koh, Karen
AU - Laslett, Andrew L
AU - Michalska, Anna
AU - Nguyen, Linh
AU - Reubinoff, Benjamin E
AU - Tellis, Irene
AU - Auerbach, Jonathan M
AU - Ording, Carol J
AU - Looijenga, Leendert H J
AU - Pera, Martin F
N1 - Funding Information:
Work in the Monash Institute of Medical Research and the Australian Stem Cell Centre was supported by the National Health and Medical Research Council,
Funding Information:
The Australian Stem Cell Centre and the National Institutes of Health (NIGMS GM68417). Work in the laboratory of L.H.J.L. was supported in part by the Dutch Cancer Society/KWF.
PY - 2006/3
Y1 - 2006/3
N2 - The application of human embryonic stem (hES) cells in regenerative medicine will require rigorous quality control measures to ensure the safety of hES cell-derived grafts. During propagation in vitro, hES cells can acquire cytogenetic abnormalities as well as submicroscopic genetic lesions, such as small amplifications or deletions. Many of the genetic abnormalities that arise in hES cell cultures are also implicated in human cancer development. The causes of genetic instability of hES cells in culture are poorly understood, and commonly used cytogenetic methods for detection of abnormal cells are capable only of low-throughput analysis on small numbers of cells. The identification of biomarkers of genetic instability in hES cells would greatly facilitate the development of culture methods that preserve genomic integrity. Here we show that CD30, a member of the tumor necrosis factor receptor superfamily, is expressed on transformed but not normal hES cells, and that CD30 expression protects hES cells against apoptosis.
AB - The application of human embryonic stem (hES) cells in regenerative medicine will require rigorous quality control measures to ensure the safety of hES cell-derived grafts. During propagation in vitro, hES cells can acquire cytogenetic abnormalities as well as submicroscopic genetic lesions, such as small amplifications or deletions. Many of the genetic abnormalities that arise in hES cell cultures are also implicated in human cancer development. The causes of genetic instability of hES cells in culture are poorly understood, and commonly used cytogenetic methods for detection of abnormal cells are capable only of low-throughput analysis on small numbers of cells. The identification of biomarkers of genetic instability in hES cells would greatly facilitate the development of culture methods that preserve genomic integrity. Here we show that CD30, a member of the tumor necrosis factor receptor superfamily, is expressed on transformed but not normal hES cells, and that CD30 expression protects hES cells against apoptosis.
KW - Biomarkers/analysis
KW - Carcinoma, Embryonal/metabolism
KW - Cell Culture Techniques
KW - Cell Differentiation
KW - Cell Line, Transformed
KW - Cell Survival
KW - Cell Transformation, Neoplastic
KW - Cells, Cultured
KW - Humans
KW - Immunohistochemistry
KW - Karyotyping
KW - Ki-1 Antigen/metabolism
KW - Pluripotent Stem Cells/cytology
UR - http://www.scopus.com/inward/record.url?scp=33644858065&partnerID=8YFLogxK
U2 - 10.1038/nbt1197
DO - 10.1038/nbt1197
M3 - Article
C2 - 16501577
SN - 1087-0156
VL - 24
SP - 351
EP - 357
JO - Nature biotechnology
JF - Nature biotechnology
IS - 3
ER -